Rabies

Table of Contents

  1. Overview
  2. Epidemiology
  3. Virology and Pathophysiology
  4. Transmission and Exposure
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment and PEP
  8. Milwaukee Protocol
  9. Prevention and Pre-Exposure Prophylaxis
  10. Prognosis
  11. Recent Research
  12. References
  13. Featured Videos

Overview

Rabies is a viral encephalitis caused by the rabies virus (RABV), a member of the genus Lyssavirus within the family Rhabdoviridae. The virion is immediately recognizable under electron microscopy by its characteristic bullet-shaped morphology — approximately 180 nm long by 75 nm wide. Once clinical symptoms appear, rabies is virtually 100% fatal, making it one of the very few infectious diseases with a near-universal case fatality rate.

Globally, rabies kills an estimated 59,000 people every year, with roughly 90% of deaths occurring in Africa and Asia. In these regions, domestic dog bites account for approximately 99% of all human rabies cases. In the United States and other high-income countries, canine rabies has been effectively eliminated through mass dog vaccination, but the virus persists in wildlife reservoirs — particularly bats, raccoons, foxes, and skunks.

Despite this grim prognosis, rabies is almost entirely preventable. Post-exposure prophylaxis (PEP) — a combination of thorough wound washing, human rabies immunoglobulin (HRIG), and a vaccine series — is essentially 100% effective when started before the onset of symptoms. The single most important immediate action after any potential exposure is washing the wound vigorously with soap and water for at least 15 minutes, which can dramatically reduce the viral load at the inoculation site.

Back to Table of Contents

Epidemiology

The World Health Organization estimates that rabies causes approximately 59,000 deaths annually, with about 95% occurring in Africa and Asia. However, because rabies is severely underreported — particularly in rural areas of endemic countries where laboratory confirmation is rarely available — the true burden is estimated to be 2 to 10 times higher than official figures suggest.

Global Distribution

United States

The USA reports only 1 to 3 human rabies deaths per year, almost all attributable to bat exposure. The last confirmed dog-to-human rabies transmission from a dog bitten in the USA occurred in 2007. This achievement — eliminating canine rabies — is one of the great public health successes of the 20th century, accomplished through widespread mandatory pet vaccination laws and stray dog control. Key US epidemiological points:

Vulnerable Populations

PEP Impact

Postexposure prophylaxis administered after approximately 15 million exposures annually is estimated to prevent 327,000 deaths per year — making rabies PEP one of the most cost-effective public health interventions available. Without PEP, the global death toll would be catastrophic.

Back to Table of Contents

Virology and Pathophysiology

Understanding how rabies virus invades, travels through, and ultimately destroys the nervous system explains both why it is so lethal and why early intervention is so critical.

Viral Structure

The rabies virion is a single-stranded, negative-sense RNA virus enclosed in a lipid envelope derived from the host cell membrane. The genome encodes exactly five proteins:

Cell Entry and Receptor Binding

The glycoprotein (G protein) binds to at least three identified receptors on neurons and other cells:

After binding, the virus enters cells by receptor-mediated endocytosis. Acidification of the endosome triggers membrane fusion, releasing the nucleocapsid into the cytoplasm where transcription begins.

Retrograde Axonal Transport

This step explains the incubation period and its variability. After initial replication at the bite site (in muscle cells), the virus is taken up by peripheral nerve endings and transported retrogradely up the axon toward the spinal cord and brain at a rate of approximately 8–20 mm per day. This transport uses the host cell's dynein motor protein complex along microtubules.

Incubation period depends on the distance from the bite to the CNS and the viral load inoculated:

CNS Invasion and Spread

Once the virus reaches the spinal cord, it spreads rapidly throughout the CNS via transsynaptic transmission. One of the virus's most remarkable (and deadly) adaptations is that it minimizes cytopathic effect in neurons — rather than killing cells outright (which would trigger inflammation and potentially alert the immune system), it modulates apoptosis pathways to keep neurons alive long enough to amplify and spread virus throughout the brain.

After CNS amplification, the virus spreads centrifugally along efferent nerves to peripheral organs — most critically to the salivary glands (enabling transmission via biting), and also to the cornea, skin hair follicles, and the heart. This centrifugal spread to the skin and cornea is the basis for ante-mortem biopsy-based diagnosis.

Cause of Death

Death in rabies results from:

Notably, gross neuropathological findings are often surprisingly mild given the severity of clinical disease — relatively little neuronal loss compared to other viral encephalitides. The dysfunction is more physiological (ion channel disruption, synaptic failure) than structural.

Back to Table of Contents

Transmission and Exposure

Rabies is a zoonotic disease — it requires transmission from an infected animal to a human. Understanding the routes and risk levels of different exposures is essential for making correct PEP decisions.

Primary Transmission Routes

Routes That Do NOT Transmit Rabies

The Bat Exposure Problem

Bats deserve special mention because they are responsible for nearly all recent human rabies deaths in the United States and Canada, and exposures are frequently unrecognized. CDC and public health guidelines specify that a person who was sleeping in a room where a bat was found — and cannot rule out that a bite occurred — should receive PEP. Bat teeth are small enough that a bite may leave no visible wound and cause no pain. This "sleep bat exposure" rule has been controversial but is based on documented cases where people died of rabies after an apparently incidental bat encounter.

PEP Decision Framework

When evaluating a potential exposure, clinicians consider:

Back to Table of Contents

Clinical Presentation

Rabies progresses through distinct phases after the incubation period. Recognizing the early signs — particularly the pathognomonic paresthesia at the bite site — can prompt urgent PEP in the rare window that might still be effective, and allows appropriate palliative planning.

Prodromal Phase (2–10 days)

The prodrome is nonspecific and easily mistaken for influenza or other common illnesses:

Furious (Encephalitic) Rabies (~80% of cases)

This is the classic presentation most people associate with rabies:

Paralytic (Dumb) Rabies (~20% of cases)

The paralytic form is frequently misdiagnosed as Guillain-Barré syndrome or other causes of acute flaccid paralysis:

Hydrophobia and Aerophobia: Why They Occur

These signs deserve emphasis because they are nearly pathognomonic. Hydrophobia is not a fear of water in the psychological sense — it is a physical laryngospasm triggered by the act of swallowing. The virus infects brainstem nuclei controlling the pharynx and larynx. The pain and terror of these spasms cause patients to refuse all liquids, leading to dehydration. Aerophobia — identical spasms triggered by a draft of air — is even more specific for rabies and should prompt immediate laboratory evaluation when present.

Back to Table of Contents

Diagnosis

Because there is no reliable blood test that diagnoses rabies in the early incubation phase, and because the virus does not generate a typical antibody response until very late in the disease course, diagnosis is challenging. Multiple sample types and testing methods are used, and no single test is 100% sensitive.

Ante-Mortem Diagnosis (Living Patient)

Important: No single ante-mortem test reliably rules out rabies early in disease. All negative results should prompt repeat testing with multiple sample types if clinical suspicion remains high.

Post-Mortem Diagnosis

Differential Diagnosis

Rabies must be distinguished from other viral encephalitides (HSV, enterovirus, West Nile, Japanese encephalitis), Guillain-Barré syndrome (in paralytic form), tetanus, delirium tremens, and hysteria. The combination of animal bite history + bite-site paresthesias + hydrophobia + aerophobia is essentially diagnostic.

Back to Table of Contents

Treatment and PEP

The cornerstone of rabies management is prevention of disease through prompt post-exposure prophylaxis. Once symptoms appear, no treatment has been proven to prevent death, and care is palliative.

Immediate First Aid After Any Exposure

Wash the wound immediately and thoroughly with soap and water for at least 15 minutes. This single step reduces the probability of infection and is the most important immediate action. Follow with application of an antiseptic such as povidone-iodine, ethanol (70%), or tincture of iodine if available. Do not suture wounds primarily if avoidable — suturing may introduce virus deeper into tissues.

Post-Exposure Prophylaxis (PEP) — Unvaccinated Person

PEP consists of two simultaneous components administered as soon as possible after exposure:

  1. Human Rabies Immunoglobulin (HRIG), 20 IU/kg:
    • Must be infiltrated directly into and around the wound(s) to neutralize virus locally before it enters nerve endings
    • Any remaining volume that cannot be anatomically infiltrated into the wound is given IM at a distant site (away from the vaccine injection site)
    • Given only on Day 0 — giving it later reduces its effectiveness and may interfere with vaccine-induced immunity
    • Do not administer in the same syringe or same anatomical site as the vaccine
    • If HRIG is not available on Day 0, administer as soon as possible within 7 days of first vaccine dose
  2. Rabies vaccine series — 4 doses IM: Days 0, 3, 7, and 14 (reduced from the former 5-dose series; FDA-approved in 2010 based on MMWR evidence)

When given before symptom onset, this regimen is essentially 100% effective. There are no documented treatment failures when PEP was correctly administered and started before symptoms appeared.

PEP — Previously Vaccinated Person

If the exposed person has previously completed a full pre-exposure or post-exposure vaccine series (confirmed by documented history or adequate RVNA titer):

Treatment of Symptomatic Rabies

Once symptoms of rabies encephalitis develop, no antiviral treatment has been proven to alter the course of disease. Management is supportive and, in most cases, palliative:

Experimental agents that have been tested without proven clinical benefit include ribavirin, interferon-alpha, and ketamine. Their use remains investigational.

HRIG Supply and Access

A major barrier to PEP effectiveness globally is the cost and availability of HRIG. In the USA, a full PEP course including HRIG costs $3,000–$10,000. In many endemic countries, HRIG is simply unavailable or unaffordable. Equine rabies immunoglobulin (ERIG) — cheaper and more widely available — is used instead in many resource-limited settings; it carries a slightly higher risk of serum sickness but is still highly effective.

Back to Table of Contents

Milwaukee Protocol

The Milwaukee Protocol is the only therapeutic strategy that has produced documented survivors of symptomatic human rabies without prior vaccination, though it has an overall success rate of only about 8% in treated patients.

Background and Rationale

In November 2004, Dr. Rodney Willoughby Jr., a pediatric infectious disease physician at Children's Hospital of Wisconsin in Milwaukee, faced an apparently hopeless case: a 15-year-old girl named Jeanna Giese who had been bitten by a bat and developed full clinical rabies without having received any pre- or post-exposure vaccination.

Willoughby's reasoning was that rabies kills through neurological dysfunction — it disrupts ion channels, neurotransmitter systems, and autonomic regulation — rather than through massive irreversible neuronal destruction. If the brain could be pharmacologically protected while the immune system mounted a response, the patient might clear the virus.

The Protocol

  1. Medically induced coma using ketamine (NMDA receptor antagonist with potential direct antiviral activity) and midazolam — to reduce cerebral metabolic demand and limit excitotoxic neuronal death
  2. Antiviral therapy with ribavirin and amantadine — chosen for their theoretical antiviral activity against RNA viruses; neither has convincingly demonstrated in vivo efficacy against RABV
  3. Intensive supportive care — mechanical ventilation, hemodynamic monitoring, seizure control, nutritional support
  4. Continued until the patient showed evidence of mounting an immune response (rising RVNA titers) and viral markers declined

Jeanna Giese: The First Survivor

Giese survived and was discharged from the hospital after 76 days, with moderate neurological deficits including ataxia and cognitive impairment. Over subsequent years, she regained substantial function and graduated from college. Her survival was extraordinary: no unvaccinated human had previously survived symptomatic rabies in recorded medical history.

Subsequent Experience

As of 2016, approximately 36 patients had been treated with versions of the Milwaukee Protocol worldwide. Only about 3 additional patients survived — an overall survival rate of approximately 8%. Analysis of the survivors reveals an important pattern: each survivor had evidence of partial or pre-existing immune response to rabies virus (either from unrecognized prior vaccination, or an unusually robust innate immune response). Patients with no immune response consistently died.

Current Status

The Milwaukee Protocol is not recommended as standard of care by any major infectious disease or neurology guideline due to its very low success rate, the enormous resource commitment required for ICU management, and the lack of meaningful benefit in immunologically naive patients. It may be considered on an individualized basis for patients who:

The primary legacy of the Milwaukee Protocol is scientific: it demonstrated for the first time that human survival is biologically possible, that immune response is the key determinant of outcome, and it prompted ongoing research into immunomodulatory and antiviral approaches.

Back to Table of Contents

Prevention and Pre-Exposure Prophylaxis

Rabies is one of the most preventable lethal infectious diseases, through a combination of pre-exposure vaccination for high-risk individuals, animal vaccination programs, wildlife reservoir management, and accessible PEP.

Pre-Exposure Prophylaxis (PrEP)

PrEP consists of a 3-dose vaccine series given on Days 0, 7, and 21 or 28. It is recommended for:

Key advantage of PrEP: if a subsequent exposure occurs, no HRIG is needed and only 2 vaccine doses (Days 0 and 3) are required — simpler, cheaper, and effective even in settings where HRIG is unavailable.

Pet and Livestock Vaccination

Rabies vaccination of dogs and cats is a core vaccine in the USA and most developed countries, required by law in most states. This single intervention eliminated dog-mediated human rabies in the USA. Mass dog vaccination campaigns in endemic countries have similarly dramatic results — Thailand reduced its annual human rabies deaths from >200 in the 1980s to <5 today through sustained canine vaccination. The WHO estimates that vaccinating 70% of the dog population in endemic areas is sufficient to eliminate the dog-to-human transmission cycle.

Oral Wildlife Bait Vaccines

RABORAL V-RG is a recombinant vaccinia-vectored oral rabies vaccine distributed in wildlife bait (fishmeal-based) dropped from aircraft across wide geographic areas. The USA has used this approach since 1990 to vaccinate raccoons, coyotes, and gray foxes. Results have been dramatic: the raccoon rabies epizootic spreading northward along the Eastern seaboard was halted at the Canadian border by a vaccine bait barrier. Similar programs in Europe eliminated fox rabies from most of Western Europe.

Wildlife Avoidance and Exposure Prevention

WHO Zero by 2030

The World Health Organization, in partnership with the Food and Agriculture Organization (FAO), World Organisation for Animal Health (OIE/WOAH), and the Global Alliance for Rabies Control, has set a target of zero human deaths from dog-mediated rabies by 2030. Mathematical modeling demonstrates this is achievable through: sustained mass dog vaccination to cover >70% of dog populations in endemic countries, accessible and affordable PEP (including intradermal regimens that reduce costs by 60–80%), and elimination of PEP stockout gaps.

Back to Table of Contents

Prognosis

The prognosis for rabies is starkly binary: almost certain survival with timely PEP, or near-certain death once symptoms appear.

With Timely PEP

Post-exposure prophylaxis correctly administered before symptom onset is essentially 100% effective. There are no documented treatment failures when:

Time from exposure to PEP initiation matters enormously. While PEP has worked up to weeks after exposure (because the virus may still be in peripheral nerves during the long incubation), delay increases risk — particularly for bites close to the head and neck.

Once Symptomatic

Fewer than 15 people have survived symptomatic rabies in recorded medical history. Most of these rare survivors:

Without prior immunity and without aggressive ICU management, survival is essentially unheard of. The virus's strategy of minimizing early cytopathic effect while spreading widely through the CNS means by the time symptoms appear, infection is already disseminated far beyond any point where local antiviral measures could be effective.

Key Prognostic Factors

The Central Message

Every hour between an animal exposure and wound washing plus PEP initiation increases risk. Rabies is one of those rare diseases where acting immediately — before waiting to see if symptoms develop — saves lives. Once symptoms appear, the window has closed. PEP must be started on the basis of exposure, not on the basis of symptoms.

Back to Table of Contents

Recent Research

Despite being one of the oldest known diseases (described in ancient Mesopotamian law codes and Greek medical texts), rabies research is advancing rapidly across multiple fronts.

Monoclonal Antibody Alternatives to HRIG

Human rabies immunoglobulin (HRIG) is expensive, produced from pooled human plasma, and in limited supply. Two neutralizing monoclonal antibodies — RVC20 (targeting the glycoprotein antigenic site III) and RVC58 (targeting antigenic site I) — form a cocktail that covers the range of rabies virus variants with potentially superior and more consistent neutralizing activity than polyclonal HRIG. Clinical trials are ongoing. If approved, this combination could dramatically reduce PEP costs and improve global access.

Intradermal PEP Regimens

WHO now endorses intradermal (ID) PEP regimens (such as the 2-site ID regimen using one-fifth the standard intramuscular dose per injection point) as equivalent to the standard IM regimen in immunogenicity. Intradermal PEP reduces the total vaccine cost by 60–80%, a transformational change for resource-limited settings. Regulatory approval of ID regimens is expanding globally.

Next-Generation Vaccines for Dog Vaccination Programs

Thermostable, single-dose, oral rabies vaccines for mass canine vaccination are under development. Current oral bait vaccines for wildlife work well but are not suitable for the scale of mass dog vaccination needed in Africa and Asia. Improved vectors and adjuvant systems aim to produce durable immunity from a single dose without a cold chain.

Antiviral Compounds

High-throughput screening has identified several promising antivirals with in vitro activity against RABV:

mRNA Vaccine Platforms

The same mRNA technology used in COVID-19 vaccines is being applied to rabies. Early-phase trials of mRNA rabies vaccines show strong immunogenicity with fewer doses and potentially more flexible production. The ability to rapidly manufacture mRNA vaccines could be critical for addressing outbreak strains.

Global Zero by 2030

Mathematical modeling published in PLOS Neglected Tropical Diseases confirms that the WHO 2030 target is achievable with current tools — mass dog vaccination reaching 70% coverage combined with accessible PEP supply chains. The primary barrier is not scientific but logistical and financial: sustained political commitment, funding for vaccines, and last-mile delivery of PEP in endemic settings. Several countries including the Philippines and Tanzania are now in the advanced stages of national elimination programs.

Back to Table of Contents

References

  1. Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4):e0003709. PMID: 25881058. PubMed
  2. Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies. MMWR Recomm Rep. 2010;59(RR-2):1–9. PMID: 20300058. PubMed
  3. Willoughby RE Jr, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med. 2005;352(24):2508–2514. PMID: 15958806. PubMed
  4. Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 2013;99(1):61–67. PMID: 23597405. PubMed
  5. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol. 2005;292:45–56. PMID: 15981457. PubMed
  6. Hanlon CA, Niezgoda M, Rupprecht CE. Postexposure prophylaxis for prevention of rabies in dogs. Clin Infect Dis. 2004;39(9):1362–1369. PubMed Search
  7. Warrell MJ, Warrell DA. Rabies: the clinical features, management and prevention of the classic zoonosis. Clin Med (Lond). 2015;15(1):78–81. PMID: 25650200. PubMed
  8. Hemachudha T, Ugolini G, Wacharapluesadee S, et al. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol. 2013;12(5):498–513. PMID: 23602163. PubMed
  9. Fooks AR, Cliquet F, Finke S, et al. Rabies. Nat Rev Dis Primers. 2017;3:17091. PMID: 29188797. PubMed
  10. WHO Expert Consultation on Rabies, third report. World Health Organ Tech Rep Ser. 2018;(1012):1–183. PubMed Search
  11. Dacheux L, Bourhy H. Advances in rabies research, an update. J Neurovirol. 2023;29:221–238. PubMed Search
  12. WHO position paper: rabies vaccines and immunoglobulins. Intradermal PEP regimens. 2018. PubMed Search

Research Papers

The following PubMed topic searches retrieve current peer-reviewed literature on Rabies.

  1. Rabies virus pathogenesis
  2. Rabies postexposure prophylaxis
  3. Rabies global burden mortality
  4. Rabies bat transmission human
  5. Rabies vaccine pre-exposure prophylaxis
  6. Milwaukee protocol rabies survival
  7. Rabies encephalitis furious paralytic
  8. Rabies Negri bodies neuropathology
  9. Rabies wound washing first aid
  10. Rabies HRIG immunoglobulin PEP
  11. Rabies zero by 2030 dog vaccination
  12. Rabies diagnosis ante-mortem RT-PCR

Connections

Back to Table of Contents